Accumulating evidence indicates that activation of the peroxisome proliferator-activated receptor-γ (PPAR-γ) dampens the inflammation cascade and inhibits tumor growth of the lung, suggesting that it has tumor suppressor functions. We performed a case-control study of 500 incident lung cancer cases and 517 age and sex frequency-matched cancer-free controls in a Chinese population to investigate the role of 11 selected single nucleotide polymorphisms (SNPs) of PPAR-γ in the etiology of lung cancer. We found that decreased lung cancer risk was statistically significantly associated with seven SNPs (P = 0.0004 for rs13073869 and 0.0130 for rs1899951 in a dominant model; P = 0.0310 for rs4135247 in a log-additive model; and P = 0.0468 for rs2972162, 0.0175 for rs709151, 0.0172 for rs11715541 and 0.0386 for rs1175543 in an overdominant model). Consistent with these results of single-locus analysis, both the haplotype and diplotype analyses revealed a protective effect of the haplotype 'AGA' and 'AAA' of rs13073869, rs1899951 and rs4135247. Furthermore, we observed a statistically significant interaction between the rs1899951 and cigarette smoking. Our results indicate that PPAR-γ polymorphisms and their interaction with smoking may contribute to the etiology of lung cancer. These findings need to be validated in larger, preferably population-based, studies including different ethnic groups.
Introduction
Lung cancer is the leading cause of cancer deaths in the world with a poor prognosis and an overall 5-year survival rate of <15% (1) . The epidemic of lung cancer is directly attributable to cigarette smoking that accounts for 87 percent of lung cancer cases (2) .
However, only a small fraction of smokers (usually <20%) develop lung cancer in their lifetime (3) , suggesting that genetic susceptibility plays a role in the development of lung cancer.
Exposure to cigarette smoke activates an inflammatory cascade in the airway epithelium. For example, tobacco smoke generates reactive oxidant species (ROS), leading to damage to the lung epithelium and its altered permeability, induction of goblet cell hyperplasia, and mucus production as well as recruitment of macrophages and neutrophils to the airway (4-7). Chronic inflammation causes prolonged irritation and activated local host response, which ultimately promote cell proliferation (8) . As a result, sustained cell proliferation facilitates tumor formation and progression in an environment abundant in inflammatory cells, growth factors, activated stroma and enhanced angiogenesis (9, 10) . Indeed, it has been estimated that cancer is preceded by chronic inflammation in up to a third of all cases (11) .
Case-control studies have shown an increased risk of lung cancer in patients with inflammatory airway phenotypes, such as asthma, bronchitis and emphysema (12) (13) (14) . Recent data suggest that cigarette smoke stimulates airway epithelial cells and immune cells to release pro-inflammatory cytokines, such as tumor necrosis factor-α (TNF-α), interleukin-4 (IL-4), interleukin-6 (IL-6), interleukin-8 (IL-8) and cyclooxygenase-2 (COX-2). The peroxisome proliferator activated receptor-γ (PPAR-γ), a ligand-activated transcription factor belonging to the nuclear receptor superfamily, has been shown to counteract inflammation by inhibiting the expression of pro-inflammatory factors, suppressing the generation of ROS and nitrogen species, inhibiting cigarette smoke-induced mucin production and dampening migratory at Pennsylvania State University on http://carcin.oxfordjournals.org/ Downloaded from responses (15) .
In addition to its anti-inflammatory effect, PPAR-γ also plays a critical role in regulating diverse processes in lung stromal/parenchymal cells, including cell-cycle control, differentiation, apoptosis, and carcinogenesis (16) (17) (18) . PPAR-γ is known to express in both human small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) cells (19) (20) (21) .
Several studies have demonstrated that the activation of PPAR-γ inhibited proliferation and growth of lung cancer cells (22) (23) (24) . PPAR-γ-selective agonists, such as 15-deoxy-delta12-14-prostaglandin J 2 (15d-PGJ 2 ) and the synthetic thiazolidinedione compounds (TZDs), certain nonsteroid anti-inflammatory drugs, lead to growth arrest, induction of apoptosis, and promotion of differentiation in cell lines (18, 20, 24) . Besides, the daily oral administration of either troglitazone or pioglitazone to the severe combined immunodeficient mice significantly reduced the number of lung metastases and restricted tumor progression in vivo (25) . Taken together, these observations suggest that PPAR-γ may act as a tumor suppressor in the pathogenesis and progression of human lung cancer.
The present work was motivated by the biological plausibility that genetic variation in the PPAR-γ gene could alter its expression level or biochemical functions and consequently may have an impact on individual risk of lung cancer. To test this hypothesis, we conducted a case-control study of 500 incident lung cancer cases and 517 age and sex frequency-matched cancer-free controls in a Chinese population, and genotyped 11 single nucleotide polymorphisms (SNPs) of PPAR-γ using an Illumina high-throughput genotyping platform. We also investigated potential interactions between polymorphisms of the PPAR-γ gene and cigarette smoking in lung cancer risk.
Materials and Methods

Study population
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The study design and subject recruitment have been described previously (26) . Briefly, 500 lung cancer patients and 517 cancer free controls were genetically-unrelated ethnic Han Chinese and were from Nanjing City and surrounding regions in southeastern China. Patients with histopathologically confirmed incident lung cancer were consecutively recruited between July 2002 and December 2004 at the Cancer Hospital of Jiangsu province (Nanjing) and the First Affiliated Hospital of Nanjing Medical University, Nanjing, China with a response rate of 90.5%. Cancer-free controls were randomly selected from 10,500 individuals who participated in a community-based screening program for non-infectious diseases conducted in Jiangsu province during the same period when the cases were recruited, with a response rate of 83.8%.
All the control subjects had no history of cancer and were frequency-matched to the cases by age (±5 years), sex, and residential area (urban or rural areas). Each participant was scheduled for an interview after a written informed consent was obtained, and a structured questionnaire was administered by interviewers to collect information on demographic data and environmental exposure history including tobacco smoking. Those who had smoked less than one cigarette per day and less than 1 year in their lifetime were defined as nonsmokers, otherwise they were considered smokers. Those smokers who had quit for longer than 1 year were considered former smokers. Pack-years smoked ([cigarettes per day /20]× years smoked) were calculated to indicate the cumulative smoking dose. Family history of cancer was defined as any self-reported cancer in first-degree relatives (parents, siblings, or children). After the interview, an approximately 5-ml venous blood sample was collected from each participant.
The study was approved by the institutional review boards of Fudan University.
Selection of single nucleotide polymorphisms of PPAR-γ
The human PPAR-γ gene is ~146 kb in size, located on chromosome 3p25. Differential promoter use and alternative splicing of the gene generate three isoforms: PPAR-γ1 and at Pennsylvania State University on http://carcin.oxfordjournals.org/ Downloaded from PPAR-γ3 protein encoding the same protein product and the PPAR-γ 2 protein containing an additional N-terminal 28 amino acid exon named exon B (27, 28) . PPAR-γ 1 is expressed in a broad spectrum of tissues, whereas PPAR-γ 2 is restricted to adipose tissue and PPAR-γ 3 is abundant in the macrophages, large intestine and white adipose tissue (16) . In the gene model (mRNA alignment) of PPAR-γ 1 (NM_005037.5), it has seven exons and six introns with more than 650 SNPs located from 2-kb upstream to 2-kb downstream as listed in the dbSNP database with a density about of 1 SNP per 200-300bp. Because this study was initiated in January 2005 when the SNP density of phase I HapMap SNP database was not adequate, we chose SNPs from both the HapMap and dbSNP databases. An algorithm to score SNPs across the gene was developed and a set of SNPs were selected based on their final scores. The procedure was described in detail in the supplementary material. In brief, for a certain SNP, the following criteria were considered: 1) inter-distance between two adjacent SNPs; 2) heterozygosity; 3) functional relevance; 4) compatibility with the genotyping platform. As a result, 11 SNPs were chosen for genotyping in this study.
Genotyping Assays
The 11 SNPs were genotyped by using the Illumina SNP genotyping BeadLab platform, which is a highly efficient genotyping assay with a combination of the Illumina Golden GateTM assay, SentrixTM array matrices and SherlockTM scanner technology (Illumina Corp, Foster City, CA), performed at the Chinese National Human Genome Center at Shanghai. The information on assay conditions and the primers and probes is available upon request. More detailed description of quality control method and each of the steps performed by the Illumina facility are available in our previously published paper (26) 
Results
Characteristics of the study population
The characteristics of the 500 lung cancer patients and 517 cancer-free controls have been described elsewhere (26) . Overall, the lung cancer cases and controls appeared to be adequately matched on age and sex (P = 0.661 and 1.000, respectively 
Association between individual SNP and risk of lung cancer
As shown in Table 1 , genotype frequency distributions of 11 SNPs in the controls were all consistent with those expected from the Hardy-Weinberg equilibrium model (all P > 0.05).
One SNP (rs1175541) in this Chinese population represented a minor allele frequency (MAF) of 6.2% lower than that reported in the dbSNP database, while the other SNPs represented a MAF at least 4.1% higher than those reported in the HapMap SNP database, which may reflect either population difference or frequency bias due to small sample sizes from which the databases derived. Allele frequencies of three SNPs were shown significant differences between the cases and the controls (P = 0.0004 for rs13073869, P = 0.0106 for rs1899951 and P = 0.0270 for rs4135247).
Significant associations were observed for two SNPs (P = 0.0004 for rs13073869 and P Table 2) .
We further evaluated the associations of the rs13073869 GA/AA and rs1899951GA/AA variant genotypes with lung cancer risk stratified by selected variables and histological types. As shown in Table 3 , compared with the common wild-type homozygous genotype, the protective effect of rs13073869 GA/AA was more evident in former smokers 
Association between haplotypes/diplotypes and risk of lung cancer
The reconstructed LD plot of 11 SNPs in 517 controls is shown in Figure 1 . Two blocks were defined by 10 SNPs and the remaining one SNP located in the downstream of block 2. Global score test showed statistically significant differences in haplotype frequency distribution between the cases and controls for Block 1 (global stat = 19.5900, df = 4, P-value = 0.0039, P-sim = 0.0027) but not for Block 2.
The logistic regression analyses revealed that the risk of lung cancer was significantly decreased among individuals carrying the haplotype 'AGA' (adjusted OR = 0.80 and 95% CI = 0.65-0.98), and 'AAA' (adjusted OR = 0.57 and 95% CI = 0.37-0.87), compared with those carrying the most common haplotype 'GGG' in block 1 (Table 4) . Notably, the 'AGA' haplotype harbored the rs13073869 A allele, and 'AAA' harbored the rs1899951 A allele as well as the forgoing one, and these two alleles were both associated with a significant decreased risk of lung cancer in the one-locus analysis. Moreover, the stratified analyses showed that the risk of lung cancer was further reduced among nonsmokers carrying the haplotype 'AAA' (adjusted OR = 0.27 and 95% CI = 0.12-0.63), but increased among heavy smokers carrying the haplotype 'GGA' (adjusted OR = 1.83 and 95% CI = 1.01-3.32).The adjusted ORs of the "GGA" versus "GGG" and "AAA" versus "GGG" increased significantly as pack-years increased, suggesting a possible interaction between "GGA" and smoking, and between "AAA" and smoking.
We also used the haplotypes within each block to build dichotomized diplotypes (0 and 1~2 copies of the haplotype). Consistent with the haplotype analyses, subjects carrying 1~2 copies of the haplotye 'AGA' had a 28% reduced lung cancer risk (adjusted OR = 0.72 and 95% CI = 0.56-0.93), and those carrying 1~2 copies of 'AAA' had a 42% reduced lung cancer risk (adjusted OR = 0.58 and 95% CI = 0.37-0.90) compared with their respective non-carriers (Supplementary material Table 2 ).
Gene-smoking interaction analysis
As shown in 
Discussion
In this lung cancer case-control study in a southeastern Chinese population, we investigated the role of multiple common variants of PPAR-γ and their interaction with cigarette exposure on the risk of lung cancer. We found that seven SNPs (rs13073869, rs1899951, rs4135247, rs2972162, rs709151, rs1175541 and rs1175543) of the 11 selected
SNPs showed a significant association with lung cancer risk. Besides, both the haplotype and diplotype analyses consistently revealed a protective effect of the haplotype 'AGA' and 'AAA' derived from rs13073869, rs1899951 and rs4135247. Moreover, we observed consistent evidence for a statistically significant interaction between the rs1899951 and cigarette smoking measured as either discrete or continuous variable. These findings support our hypothesis that PPAR-γ polymorphisms and their interaction with smoking may contribute to the etiology of lung cancer. This is, to the best of our knowledge, the first study to assess the association between a broad spectrum of genetic variants individually and collectively as haplotyes of the PPAR-γ gene and lung cancer risk.
The most outstanding finding in this study was the consistency in genotypic, haplotypic and diplotypic associations of rs13073869 and rs1899951 with lung cancer risk. In the In the single locus analysis, we found that the protective effect appeared to be significant in the heterozygotes but not in homozygotes. Although current knowledge does not provide a convincing explanation for such a finding, there are several possibilities that may lead to the seemingly peculiar finding. Technically, although such a bias towards the heterozygotes could result from a systematic error, particularly in the genotyping using restriction enzymes, this is unlikely to occur in the Illumina assay for genotyping using variant-specific probes. In a strictly genetic sense without any selection bias, such data apparently well fit an overdominant model, in which heterozygous genotype confers a higher fitness compared with the corresponding homozygous genotypes. Molecularly, this is consistent with such a hypothesis -that is, if PPAR-γ performs its function within an optimal There are three main strengths of this study. First, several previous studies have assessed single variants in PPAR-γ for associations with diseases, but mostly focusing on only one or two variants in the coding region or promoter region and none of the polymorphisms genotyped in our study has been investigated in reported association studies. As lung cancer is a multifactorial disease likely involving multiple SNPs in multiple genes, we evaluated a broader spectrum of PPAR-γ variants individually as alleles and collectively as haplotypes, which may be more powerful than that of analyzing a single allele or locus. Second, all diagnoses of lung cancer were confirmed histologically, and complete smoking data were collected systematically. The adjusted ORs in both stratified and joint-effect analyses for different pack-year categories of smoking were similar in magnitude and direction to the point estimates obtained from fitted ORs of the interaction models. The consistency of these results suggests that our findings are unlikely due to chances. Finally, an investigation of a candidate gene needs many SNPs for individual association analysis (44, 45 false-positive (type I error) rate under nominal significance thresholds (e.g., α=0.05). One the other hand, when background LD exists between SNPs but they are assumed to be completely independent, then the popular Bonferroni correction would cause overcorrection for the inflated false-positive rate, resulting in a reduction in study power (46) . For calculating the significance of SNPs in LD with each other, a permutation test has been suggested to adjust for multiple testing while preserving the correlation structure among linked markers (47-50). By using this method, the false-positive rate for a large number of tests was satisfactorily controlled in our study.
Despite the strengths and biologic plausibility of the associations observed in our study, inherited biases in the present study may have led to spurious findings. First of all, the lung cancer cases were enrolled from the hospitals and the controls were selected from the surrounding communities, inherent selection bias cannot be completely excluded. However, by matching the controls to the cases on age, sex, and residential area (urban or rural), the potential confounding factors may be minimized. Second, the sample size of our study may not be large enough either to detect a small effect from very low-penetrance SNPs or to identify significant associations of the effect in different strata in subgroup analysis adequately. Third, except for cigarette smoking, the information on other factors such as occupational exposure and certain dietary components, which might interact with PPAR-γ genotypes or act as potential confounding factors, were not available in our study. Possible interactions between PPAR-γ genotypes and these risk factors should be thoroughly investigated in future studies.
Finally, since the phase II HapMap was not accomplished when we selected SNPs for genotyping, our genotyping efforts were limited because we chose SNPs from both HapMap public SNP database of phase I and dbSNPs database available to us and the 11 SNPs in PPAR-γ we genotyped were not enough to capture or represent all genetic variants of this gene based on our current knowledge. In the newly released data in phase II of the International In conclusion, our study provided evidence for the first time that the PPAR-γ polymorphisms and their interactions with cigarette smoking may contribute to the etiology of lung cancer in a Chinese population. Furthermore, we also showed that a genetic susceptibility, coupled with a modifiable lifestyle factor (such as cigarette smoking), appeared to have conferred a significantly higher risk of lung cancer than either factor alone. However, these findings need to be substantiated by larger studies with diverse ethnic populations. c MAF, minor allele frequency, from both HapMap and dbSNP databases, the MAF in bold is from the dbSNP database.
d P value for difference in allele distributions between cases and controls.
e Generated by permutation test with 10,000 times permutation.
f HWE, Hardy-Weinberg Equilibrium, HWE P value in the control group. OR, odds ratio, CI, confidence interval. a Adjusted for age, sex, pack-years of smoking, and family history of cancer, accordingly.
b Those who had smoked less than one cigarette per day and less than 1 year in their lifetime were defined as nonsmokers; those smokers who had quit for longer than 1 year were considered former smokers; otherwise they were considered current smokers. c Large cell, mixed cell carcinomas or undifferentiated carcinoma. OR, odds ratio; CI, confidence interval. a Polymorphic bases were in 5'-3' order as listed in table1.Loci chosen for Block1:SNP1-3; Loci chosen for Block2: SNP5-10.
b Generated by permutation test with 10,000 times simulation.
c Adjusted for age, sex, pack-years of smoking and family history of cancer.
d Adjusted for age, sex, and family history of cancer. 
